
Gregory Reaman MD
Gregory H. Reaman, M.D. joined the Center for Drug Evaluation and Research, Office of New Drugs, U.S. Food and Drug Administration as the Associate Director of the Office of Oncology Drug Products in 2011. He is the Founding and Immediate Past Chair of the Children's Oncology Group (COG) having served in this capacity from 2000 through 2010. The COG is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer.
Dr. Reaman is a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the Children's National Medical Center in Washington, D.C., which he directed for more than 17 years and Executive Director Emeritus of the Center for Cancer and Blood Disorders.
Dr. Reaman serves or has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query (PDQ), National Cancer Institute as well as www.PLWC.org (People Living with Cancer, now Cancer.net). He has served as an Associate Editor of Cancer and Leukemia and Lymphoma. He held the position of Executive Director for Scientific and Medical Affairs for the National Childhood Cancer Foundation (NCCF) and was a member of its Board of Trustees. Previously, he served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer. Dr. Reaman served on the Board of Directors of the American Society of Clinical Oncology (ASCO) and has served on the ASCO Patient Education Committee, the Education and Program Committees, the Cancer Research Committee, the Grant Selection Committee, Cancer Survivorship Committee, and served as Chair of the ASCO Membership and Audit Committees. Also, he was a member of the Food and Drug Administration's Oncologic Drugs Advisory Committee and has chaired its Pediatric Subcommittee. He was a member of the NIH Roadmap Working Group. He serves on the Scientific Steering Committee of the United Kingdom Children's Cancer and Leukemia Group, the External Advisory Board of the Cancer Treatment and Research Center at the University of Texas Health Science Center at San Antonio and is a Senior Advisor to the Middle East Childhood Cancer Alliance (MECCA).
Additionally, he is a member of the Alliance for Childhood Cancer, a member of the Data Safety Monitoring Board of the National Cancer Institute's Clinical Oncology Program, and a member of the NCI's Translational Research Working Group. His research interests are in the biology and treatment of childhood acute leukemia and new drug development for pediatric cancers.<br><br>He is the author of more than 300 peer-reviewed manuscripts and 16 book chapters.
Close